Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report
| Autor: | Sidney H. Kennedy, Wendy Lou, Sagar V. Parikh, Raymond W. Lam, Susan Rotzinger, Emma Morton, Peter Giacobbe, Daniel J. Müller, Erin E. Michalak, Roumen Milev, Can-Bind Investigator Team, Trisha Chakrabarty, Benicio N. Frey, Venkat Bhat |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Aripiprazole Citalopram 03 medical and health sciences 0302 clinical medicine Quality of life Internal medicine mental disorders medicine Humans Escitalopram Pharmacology (medical) In patient Depression (differential diagnoses) Depressive Disorder Major business.industry General Medicine medicine.disease humanities 030227 psychiatry Psychiatry and Mental health Treatment Outcome Quality of Life Treatment strategy Major depressive disorder Antidepressant Drug Therapy Combination business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Pharmacopsychiatry. 54:225-231 |
| ISSN: | 1439-0795 0176-3679 |
| DOI: | 10.1055/a-1385-0263 |
| Popis: | Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders ( Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|